APA (7th ed.) Citation

N, N. (2025). Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial". Clinical and molecular hepatology, 31(1), 311. https://doi.org/10.3350/cmh.2024.0739

Chicago Style (17th ed.) Citation

N, Nishida. "Personalized Approaches to the Treatment of Hepatocellular Carcinoma Using Immune Checkpoint Inhibitors: Editorial on "Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial"." Clinical and Molecular Hepatology 31, no. 1 (2025): 311. https://doi.org/10.3350/cmh.2024.0739.

MLA (9th ed.) Citation

N, Nishida. "Personalized Approaches to the Treatment of Hepatocellular Carcinoma Using Immune Checkpoint Inhibitors: Editorial on "Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial"." Clinical and Molecular Hepatology, vol. 31, no. 1, 2025, p. 311, https://doi.org/10.3350/cmh.2024.0739.